 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Seattle Children's Research Institute (SCRI)/DGH, University of Washington |
| Street 1: | Center for Global Infectious Disease Research (CGIDR) |
| Street 2: | 1900 9th Ave |
| City: | Seattle |
| Province: | WA |
| Post Code: | 98101 |
| Country: | United States of America |
| Phone: | 2068843336 |
| Organization Email: | Rhea.Coler@seattlechildrens.org |
| Web Site: | http://www.seattlechildrens.org/research/ |
| Other Online Presence: | http://www.seattlechildrens.org/research/centers-programs/global-infectious-disease-research/research-areas-and-labs/coler-lab/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 91-0564748 |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Organization Description: | |
| Seattle Children's Research Institute (SCRI) is one of the top five pediatric research centers in the USA. For the past 15 years, SCRI has been at the forefront of breakthrough innovations. From new drugs to treat cystic fibrosis, to first-in-the-nation use of laser ablation for epilepsy and brain tumors, the research division is advancing our mission to provide hope, care and cures to help every child and their families live the healthiest and most fulfilling life possible. When the research institute was officially established in 2006, there were 40 employees dedicated to research and 20,000 square feet of research space. Today we have a workforce of more than 2,000 and have expanded the footprint of our research campus to over 1.1 million square feet. Our researchers are working in many different areas of importance for childhood health supported by over $200 million of extramural fundingIn order to accelerate research progress, the institute is divided into seven centers; each one specializes in specific investigative areas. Most of the tuberculosis research occurs at the Center for Global Infectious Disease Research (CGIDR). | |
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Delivery of health services and care Research and Development Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 51 - 99 |
| Number of part-time staff who are directly involved with TB: | 100 + |
| Number of volunteers who are directly involved with TB: | 6 - 10 |
| How did you hear about the Stop TB Partnership: | Unknown |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We are developing novel treatments and vaccines for tuberculosis. WE have invested in state-of-the-art BSL3 facilities where much of our tuberculosis research is conducted. | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Netherlands Philippines Republic of Korea South Africa United Kingdom of Great Britain and Northern Ireland United States of America Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: We are involved in vaccine development (subunit vaccines, RNA vaccines, Phage and host-directed therapies for tuberculosis. Laboratory Strengthening: In collaboration with biotech and academic groups in the Republic of Korea. New TB Vaccines: Co-inventor of both M72 and ID93 vaccine antigens, both in clinical testing. We also have a handful of new generation candidate vaccines that have shown protection against Mtb HN878 in short term mouse models of tuberculosis. Research: The goal of my IMPAc-TB contract is to comprehensively identify the complex immune responses required to prevent Mtb infection or active TB disease by comparing and interrogating the mycobacteria- and vaccine-induced protective immunity in several animal species and in man. The overarching paradigm of this project is that identification and validation of common protective correlates of immunity against Mtb (a NIAID Category C pathogen) in escalating preclinical animal models of TB, NTM exposure, and human challenge experimental medicine clinical studies, will be crucial in the rational design and development of candidate vaccines that generate robust levels of durable, protective immunity against TB. |
|
Declaration | |
| Declaration of interests: None | |
| Application date: | July 7, 2024 |
| Last updated: | April 3, 2025 |